Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 85Years
All Genders
NCT06853015

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

Led by Shirley Ryan AbilityLab · Updated on 2025-04-03

27

Participants Needed

1

Research Sites

56 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.

CONDITIONS

Official Title

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and females between ages 18-85 years
  • Spinal cord injury at least 6 months post injury
  • Spinal cord injury at or above L2
  • ASIA A, B, C, or D, complete or incomplete injury
  • Ability to perform a small visible contraction with dorsiflexion and hip flexor muscles
Not Eligible

You will not qualify if you...

  • Uncontrolled medical problems including pulmonary, cardiovascular, or orthopedic disease
  • Any history of renal impairment
  • Any debilitating disease prior to the SCI causing exercise intolerance
  • Premorbid, ongoing major depression or psychosis, or altered cognitive status
  • History of head injury or stroke
  • Vascular, traumatic, tumoral, infectious, or metabolic brain lesion without seizure history or anticonvulsant medication
  • History of seizures or epilepsy
  • Use of drugs lowering seizure threshold acting on the central nervous system
  • Pregnant females
  • Women of childbearing age unsure of pregnancy who decline pregnancy test
  • Ongoing cord compression or syrinx in the spinal cord or spinal cord diseases such as spinal stenosis, spina bifida, multiple sclerosis, or herniated disk
  • Metal plate in skull
  • Presence of scalp shrapnel, cochlear implants, or aneurysm clips
  • Taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, or drugs prolonging PR interval

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shirley Ryan Abilitylab

Chicago, Illinois, United States, 60611

Actively Recruiting

Loading map...

Research Team

M

Monica Perez, PT, PhD

CONTACT

B

Bing Chen, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here